The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women

Journal of Clinical Investigation

Volumn 102, Issue 5, 1998, Pages 1035-1040

  O'Sullivan, Anthony J ^a   Crampton, Leonie J ^a   Freund, Judith ^a   Ho, Ken K Y ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Body composition; Estrogen; Growth hormone; Insulin like growth factor I; Metabolism

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; LUTEINIZING HORMONE; SOMATOMEDIN C;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BONE DENSITY; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ENERGY EXPENDITURE; ENERGY METABOLISM; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HUMAN; LEAN BODY WEIGHT; LIPID OXIDATION; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0032168320     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI2773     Document Type: Article

References (44)

1. Weissberger, A.J., K.K.Y. Ho, and L. Lazarus. 1991. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I and GH-binding protein in postmenopausal women. J. Clin. Endocrinol. Metab. 72:374-381.
2. Kelly, J.J., I.A. Rajkovic, A.J. O'Sullivan, C. Sernia, and K.K.Y. Ho. 1993. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clin. Endocrinol. (Oxf.). 39:561-567.
3. Jorgensen, J.O.L., L. Theusen, T. Ingemann-Hansen, S.A. Pedersen, J. Jorgensen, and J.S. Christiansen. 1989. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1:1221-1225.
4. Salomon, F., R.C. Cuneo, R. Hesp, and P.H. Sonksen. 1989. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321: 1797-1803.
5. Moller, N., J.O.L. Jorgensen, K.G. Alberti, A. Flyvbjerg, and O. Schmitz. 1990. Short-term effects of growth hormone on fuel oxidation and regional substrate metabolism in normal man. J. Clin. Endocrinol. Metab. 70:1179-1186.
6. O'Sullivan, A.J., J.J. Kelly, D.M. Hoffman, J. Freund, and K.K.Y. Ho. 1994. Body composition and energy expenditure in acromegaly. J. Clin. Endocrinol. Metab. 78:381-386.
7. Hoffman, D.M., A.J. O'Sullivan, J. Freund, and K.K.Y. Ho. 1995. Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism. J. Clin. Endocrinol. Metab. 80:72-77.
8. Mannor, D.A., L.M. Winer, M.A. Shaw, and G. Baumann. 1991. Plasma growth hormone binding (GH) proteins: effects on GH binding to receptors and on GH action. J. Clin. Endocrinol. Metab. 73:30-34.
9. Lim, L., S.A. Spencer, P. McKay, and M.J. Waters. 1990. Regulation of growth hormone (GH) bioactivity by a recombinant human GH-binding protein. Endocrinology. 127:1287-1291.
10. Powers, M.S., L. Schenkel, P.E. Darley, W.R. Good, J.C. Balestra, and V.A. Place. 1985. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am. J. Obstet. Gynecol. 152:1099-1106.
11. Chetkowski, R.J., D.R. Meldrum, K.A. Steingold, D. Randle, J.K. Lu, P. Eggena, J.M. Hershman, N.K. Alkjaersig, A.P. Fletcher, and H.L. Judd. 1986. Biological effects of transdermal estradiol. N. Engl. J. Med. 314:1615-1620.
12. O'Sullivan, A.J., and K.K.Y. Ho. 1995. A comparison of the effects of oral and transdermal estrogen replacement therapy on insulin sensitivity in postmenopausal women. J. Clin. Endocrinol. Metab. 80:1783-1788.
13. O'Sullivan, A.J., J.J. Kelly, D.M. Hoffman, R.C. Baxter, and K.K.Y. Ho. 1995. Energy metabolism and substrate oxidation in acromegaly. J. Clin. Endocrinol. Metab. 80:486-491.
14. Ferrannini, E. 1988. The theoretical bases of indirect calorimetry: a review. Metabolism. 37:287-301.
15. Ho, K.Y., A.J. Weissberger, P. Marbach, and L. Lazarus. 1990. Therapeutic efficacy of the somatostatin analog 201-995 (octreotide) in acromegaly: effects of dose and frequency and long-term safety. Ann. Intern. Med. 112:173-181.
16. Baxter, R.C., A.S. Brown, and J.R. Turtle. 1982. Radioimmunoassay for somatomedin C: comparison with radioreceptor assay in patients with growth-hormone disorders, hypothyroidism, and renal failure. Clin. Chem. 28:488-495.
17. Grizzle, J.E. 1965. The two-period change-over design and its use in clinical trials. Biometrics. 21:467-480.
18. Writing group for the PEPI trial. 1995. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA (J. Am. Med. Assoc.). 273:199-208.
19. Goldzieher, J.W., L.E. Moses, E. Averkin, C. Scheel, and B.Z. Taber. 1971. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil. Steril. 22:609-623.
20. Pratt, W.F., and C.A. Bachrach. 1989. What do women use when they stop using the pill? Fam. Plann. Perspect. 19:257-266.
21. Riddoch, G.G., P. Duncombe, and G.T. Kovacs. 1966. Tasmanian survey of pill symptoms. Aus. Fam. Phys. 25:S38-S40.
22. Suter, P.M., Y. Schutz, and E. Jequier. 1992. The effect of ethanol on fat storage in healthy subjects. N. Engl. J. Med. 326:983-987.
23. Zurlo, F., S. Lillioja, P. Esposito-Del, B.L. Nyomba, I. Raz, M.F. Saad, B.A. Swinborn, W.C. Knowler, C. Bogardus, and E. Ravussin. 1990. Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. Am. J. Physiol. 259:E650-E657.
24. Walker, J.L., M. Ginalska-Malinowska, T.E. Romer, J.B. Pucilowska, and L.E. Underwood. 1991. Effects of the infusion of insulin-like growth factor 1 in a child with growth hormone insensitivity syndrome (Laron Dwarfism). N. Engl. J. Med. 324:1483-1488.
25. Mauras, N., and B. Beaufrere. 1995. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetegenic effect. J. Clin. Endocrinol. Metab. 80:869-874.
26. Hussain, M.A., O. Schmilz, A. Mengel, Y. Glatz, J.S. Christiansen, J. Zapf, and E.R. Froesch. 1994. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J. Clin. Invest. 94:1126-1133.
27. O'Sullivan, A.J., D.H. Hoffman, and K.K.Y. Ho. 1995. Estrogen, lipid oxidation and body fat. N. Engl. J. Med. 333:669-670.
28. Moller, J., J.O.L. Jorgensen, N. Moller, J.S. Christiansen, and J. Weeke. 1992. Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. Metabolism. 7:728-731.
29. 14C] oleate by perfused livers and hepatocytes from female rats. Biochem. J. 180:265-271.
30. Ockner, R.K., N. Lysenko, J.A. Manning, S.E. Monroe, and D.A. Burnett. 1980. Sex steroid modulation of fatty acid utilization and fatty acid binding protein concentration in rat liver. J. Clin. Invest. 65:1013-1023.
31. Walsh, B.W., I. Schiff, B. Rosner, L. Greenberg, V. Ravnikar, and F.M. Sacks. 1991. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. 325:1196-1204.
32. Forbes, G.B. 1987. Human body composition. In Growth, Aging, Nutrition, and Activity. Springer-Verlag, New York. 169-195.
33. Rudman, D. 1985. Growth hormone, body composition and aging. J. Am. Geriatr. Soc. 33:800-807.
34. Forbes, G.B., and J.C. Reina. 1970. Adult lean body mass declines with age:some longitudinal observations. Metabolism. 19:653-663.
35. Novak, J.P. 1972. Aging, total body potassium, fat-free mass and cell mass in males and females between 18 and 85 years. J. Gerontol. 27:653-663.
36. Gutthann, S.P., L.A.G. Rodriguez, J. Castellsague, and A.D. Oliart. 1997. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 314:796-800.
37. Stampfer, M.J., G.A. Colditz, W.C. Willett, J.E. Manson, B. Rosner, F.E. Speizer, and C.H. Hennekens. 1991. Postmenopausal estrogen therapy and cardiovascular disease. N. Engl. J. Med. 325:756-762.
38. Nabulsi, A.A., A.R. Folsom, A. White, W. Patsch, G. Heiss, K.K. Wu, and M. Szklo. 1993. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N. Engl. J. Med. 328: 1069-1075.
39. Barrett-Connor, E., D.L. Wingard, and M.H. Criqui. 1989. Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA (J. Am. Med. Assoc.). 261:2095-2100.
40. Manolio, T.A., C.D. Furberg, L. Shemanski, B.M. Psaty, D.H. O'Leary, R.P. Tracy, and T.L. Bush. 1993. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation. 88: 2163-2171.
41. Goldman, L., and A.N.A. Tosteson. 1991. Uncertainty about postmenopausal estrogen. N. Engl. J. Med. 325:800-802.
42. Barrett-Connor, E. 1991. Postmenopausal estrogen and prevention bias. Ann. Intern. Med. 115:455-456.
43. Petitti, D.B., J.A. Perlman, and S. Sidney. 1986. Postmenopausal estrogen use and heart disease. N. Engl. J. Med. 315:131-132.
44. Posthuma. W.F.M., R.G.J. Wstendorp, and J.P. Vandenbroucke. 1994. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased. BMJ. 308:1268-1269.